Short-Term Results of Treating Primary and Recurrent Anal Fistulas with a Novel Extracellular Matrix Derived from Porcine Urinary Bladder

Anal fistulas are difficult to treat because they are often recalcitrant to medical therapies and surgical treatment may lead to significant morbidities. A recent novel biologically derived graft from porcine urinary bladder (MatriStem (TM)) has shown great promise in experimental studies of tissue regeneration in diverse tissues. The objectives of this study were to evaluate the safety and short-term efficacy of MatriStem for treatment of anal fistulas. This was a retrospective study of patients treated from January 3, 2012 to March 3, 2014 at the University of Pittsburgh Medical Center. MatriStem was used to treat patients with anal fistulas by implanting it uniformly with a single application in all patients using a standardized protocol. Data were collected retrospectively from hospital records and office charts. Nineteen fistulas were treated with MatriStem. There were no adverse complications. Overall efficacy of MatriStem was 79 per cent with healing occurring in a mean time of 17 days and mean follow-up of seven months (range 1-26 months). MatriStem was effective in healing in 75 per cent of primary anal fistulas and 86 per cent of recurrent fistulas. MatriStem seems to be a safe and promising treatment for primary and recurrent anal fistulas, and warrants further study and clinical trials to substantiate widespread clinical use.